journal article·2025-03Open access

Chromosome Missegregation Triggers Tumor Cell Pyroptosis and Enhances Anti‐Tumor Immunotherapy in Colorectal Cancer

Wei Duan, Rendy Hosea, Lingxian Wang, Cao Ruan, Fuqiang Zhao, Jingyi Liu, Hezhao Zhao, Makoto Miyagishi, Shourong Wu, Vivi Kasim

Advanced Science· Volume 12· Issue 12

Abstract

Abstract Immune checkpoint inhibitor (ICI) therapy is a promising anti‐tumor therapeutic strategy; however, its efficacy in solid tumors is limited. Chromosome missegregation is common in various solid tumors; however, its role in tumor progression remains poorly understood, and its correlation with ICI is yet to be explored. Here, it is found that increased chromosome missegregation promotes tumor immune microenvironment, and eventually immunotherapeutic efficacy, by triggering pyroptosis. yin yang 2 (YY2) is identified as a mitotic checkpoint regulator, which promotes chromosome missegregation by upregulating BUB1B transcription. Increased chromosome missegregation promoted the formation of micronuclei and release of double‐stranded DNA (dsDNA) into the cytosol, triggering an AIM2‐mediated cytosolic dsDNA response. The subsequent pyroptosis strengthened the tumor immune microenvironment, thereby enhancing immunoinfiltration and cytotoxicity of CD8+ T cells, while preventing their exhaustion. Finally, through in vitro and in vivo experiments, it is demonstrated that combining YY2 overexpression‐induced chromosome missegregation/cytosolic dsDNA response and PD‐1 inhibitor significantly enhanced the efficacy of ICI immunotherapy in microsatellite instable and microsatellite stable colorectal cancer cells. Together, these findings provide new insights on the role of chromosome missegregation in triggering cytosolic dsDNA response‐mediated pyroptosis and modulating the tumor immune microenvironment, suggesting a novel strategy for improving ICI therapeutic efficacy in colorectal cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · interferon and immune responses · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Biorheological Science and Technology Ministry of Education College of Bioengineering Chongqing University Chongqing 400044 China

The 111 Project Laboratory of Biomechanics and Tissue Repair College of Bioengineering Chongqing University Chongqing 400044 China

Department of Gastrointestinal Surgery Chongqing University Cancer Hospital Chongqing University Chongqing 400030 China

Life Science Innovation School of Integrative and Global Majors University of Tsukuba Tsukuba Ibaraki 305‐0006 Japan

Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment Chongqing University Cancer Hospital Chongqing University Chongqing 400030 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Chongqing Municipality

References (60)

Show source-provided references
1. 10.1038/s41467-022-34156-110.1038/s41467-022-34156-1 ↗
2. 10.1016/j.molcel.2019.09.03010.1016/j.molcel.2019.09.030 ↗
3. 10.1158/2326-6066.CIR-20-058610.1158/2326-6066.CIR-20-0586 ↗
4. 10.1038/s41392-023-01522-410.1038/s41392-023-01522-4 ↗
5. 10.1016/j.devcel.2021.07.00910.1016/j.devcel.2021.07.009 ↗
6. 10.1158/0008-5472.CAN-18-323510.1158/0008-5472.CAN-18-3235 ↗
7. 10.1101/gad.314351.11810.1101/gad.314351.118 ↗
8. 10.1038/nbt.220310.1038/nbt.2203 ↗
9. 10.1038/nrm402510.1038/nrm4025 ↗
10. 10.1038/nature2543210.1038/nature25432 ↗
11. 10.1158/0008-5472.CAN-10-360410.1158/0008-5472.CAN-10-3604 ↗
12. 10.1016/j.ccr.2005.06.01110.1016/j.ccr.2005.06.011 ↗
13. 10.1038/s41392-024-01767-710.1038/s41392-024-01767-7 ↗
14. 10.1038/s41467-021-23965-510.1038/s41467-021-23965-5 ↗
15. 10.1126/scitranslmed.abd481110.1126/scitranslmed.abd4811 ↗
16. 10.1016/j.celrep.2015.06.06510.1016/j.celrep.2015.06.065 ↗
17. 10.1016/j.cell.2018.08.02710.1016/j.cell.2018.08.027 ↗
18. 10.1038/s41568-022-00544-410.1038/s41568-022-00544-4 ↗
19. 10.1038/s41586-022-04738-610.1038/s41586-022-04738-6 ↗
20. 10.1038/s41586-022-04789-910.1038/s41586-022-04789-9 ↗
21. 10.7554/eLife.5008710.7554/eLife.50087 ↗
22. 10.1038/nrc278110.1038/nrc2781 ↗
23. 10.1002/advs.20210483610.1002/advs.202104836 ↗
24. 10.1038/s41467-023-36881-710.1038/s41467-023-36881-7 ↗
25. 10.1073/pnas.161554011310.1073/pnas.1615540113 ↗
26. 10.1002/advs.20220734910.1002/advs.202207349 ↗
27. 10.1038/s41580-023-00593-z10.1038/s41580-023-00593-z ↗
28. 10.1016/j.cell.2023.11.04410.1016/j.cell.2023.11.044 ↗
29. 10.1016/j.molcel.2021.09.00310.1016/j.molcel.2021.09.003 ↗
30. 10.1016/j.immuni.2016.04.01910.1016/j.immuni.2016.04.019 ↗
31. 10.1038/s41392-021-00507-510.1038/s41392-021-00507-5 ↗
32. 10.1111/imr.1229610.1111/imr.12296 ↗
33. 10.1038/nature0772510.1038/nature07725 ↗
34. 10.1038/s41586-018-0534-z10.1038/s41586-018-0534-z ↗
35. 10.1016/j.cell.2013.06.00710.1016/j.cell.2013.06.007 ↗
36. 10.1016/j.febslet.2006.10.02310.1016/j.febslet.2006.10.023 ↗
37. 10.1038/cdd.2012.13510.1038/cdd.2012.135 ↗
38. 10.1016/j.devcel.2012.06.01310.1016/j.devcel.2012.06.013 ↗
39. 10.1016/j.celrep.2017.05.02110.1016/j.celrep.2017.05.021 ↗
40. 10.1038/celldisc.2017.3510.1038/celldisc.2017.35 ↗
41. 10.1146/annurev-pathol-042020-04274110.1146/annurev-pathol-042020-042741 ↗
42. 10.1038/s41586-020-2079-110.1038/s41586-020-2079-1 ↗
43. 10.1056/NEJMoa201769910.1056/NEJMoa2017699 ↗
44. 10.1101/cshperspect.a02961110.1101/cshperspect.a029611 ↗
45. 10.1016/j.ccell.2020.07.00410.1016/j.ccell.2020.07.004 ↗
46. 10.1038/s43018-023-00610-210.1038/s43018-023-00610-2 ↗
47. 10.1016/S0140-6736(21)01206-X10.1016/S0140-6736(21)01206-X ↗
48. 10.1016/j.critrevonc.2022.10366310.1016/j.critrevonc.2022.103663 ↗
49. 10.1053/j.gastro.2023.11.29410.1053/j.gastro.2023.11.294 ↗
50. 10.1038/s41467-023-41618-710.1038/s41467-023-41618-7 ↗
51. 10.1016/j.trecan.2023.07.00210.1016/j.trecan.2023.07.002 ↗
52. 10.1038/358167a010.1038/358167a0 ↗
53. 10.1126/science.aay387810.1126/science.aay3878 ↗
54. 10.1016/j.immuni.2023.10.00410.1016/j.immuni.2023.10.004 ↗
55. 10.1016/j.cell.2014.04.00710.1016/j.cell.2014.04.007 ↗
56. 10.1016/j.cub.2020.02.02110.1016/j.cub.2020.02.021 ↗
57. 10.1089/15454570332261700510.1089/154545703322617005 ↗
58. 10.1158/0008-5472.CAN-17-404710.1158/0008-5472.CAN-17-4047 ↗
59. 10.1016/j.immuni.2020.07.00910.1016/j.immuni.2020.07.009 ↗
60. 10.1016/j.cell.2019.05.03110.1016/j.cell.2019.05.031 ↗